John Johnson has a good reason today to be thankful for his new job at Dendreon: He won't have to face the music at Savient.
In the course of one short year, Dendreon CEO Mitch Gold went from biotech hero to zero as the long-anticipated rollout of the groundbreaking cancer vaccine Provenge stumbled badly out of the gate.
Woe is Savient Pharmaceuticals. The company finally succeeded in getting its gout drug Krystexxa approved by FDA--its first and only product so far--but lacks the money for a major launch. And its
Savient Pharmaceuticals has won FDA approval for Kyrstexxa (pegloticase), a closely-watched drug for chronic gout in adult patients refractory to conventional therapy. Gout, which affects more than 5
Brian Orelli of The Motley Fool highlights four drugs--AstraZeneca's Brilinta, Questcor's Acthar Gel, Savient's Krystexxa and Novartis' Gilenia--that could gain FDA approval this month despite some
Shares of Savient Pharmaceuticals (SVNT) were up as much as 5 percent today on rumors that Amgen is interested in acquiring the company. Savient has submitted a BLA for its closely-watched gout drug
Savient Pharmaceuticals (SVNT) today announced plans to reduce costs by slashing its headcount by 38 percent--or 26 jobs--as it prepares to resubmit its BLA for investigational gout drug Krystexxa.
Savient Pharmaceuticals says it's on track to resubmit its closely-watched gout drug for FDA marketing approval by the early part of 2010 after the FDA made it clear in a recent meeting that the
Savient Pharmaceuticals announced on Sunday that the FDA issued a complete response letter for the drugmaker's gout drug Krystexxa (pegloticase), causing the company's shares to fall 38 percent in
Shares of Savient Pharmaceuticals barreled ahead more than 50 percent this morning after analysts had a chance to digest FDA staff remarks on the gout drug Krystexxa, which is up for a panel review